congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Edoxaban
EHRA 2024 | April 7-9, 2024
Decoding definitions of major bleeding in retrospective observational studies on direct oral anticoagulants for atrial fibrillation: A targeted literature review
Poster
Edoxaban
EHRA 2024 | April 7-9, 2024
Impact of different dose reduction criteria on dose assignment of current DOACs and related outcomes: An analysis from 4-year data of the ETNA-AF Europe programme
Poster
Edoxaban
EHRA 2024 | April 7-9, 2024
Management of edoxaban therapy in patients undergoing emergency/urgent procedures: A subanalysis of the global prospective, observational, multinational EMIT-AF/VTE programme